Cargando…

A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin

BACKGROUND: Influenza viruses, especially Influenza A virus and Influenza B virus, are respiratory pathogens and can cause seasonal epidemics and pandemics. Severe influenza viruses infection induces strong host-defense response and excessive inflammatory response, resulting in acute lung damage, mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Rongbo, Lv, Chaoxiang, Wang, Tiecheng, Deng, Xiuwen, Sima, Mingwei, Guo, Jin, Qi, Jing, Sun, Weiyang, Shen, Beilei, Li, Yuanguo, Yue, Donghui, Gao, Yuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621105/
https://www.ncbi.nlm.nih.gov/pubmed/37919750
http://dx.doi.org/10.1186/s13020-023-00843-4
_version_ 1785130343377928192
author Luo, Rongbo
Lv, Chaoxiang
Wang, Tiecheng
Deng, Xiuwen
Sima, Mingwei
Guo, Jin
Qi, Jing
Sun, Weiyang
Shen, Beilei
Li, Yuanguo
Yue, Donghui
Gao, Yuwei
author_facet Luo, Rongbo
Lv, Chaoxiang
Wang, Tiecheng
Deng, Xiuwen
Sima, Mingwei
Guo, Jin
Qi, Jing
Sun, Weiyang
Shen, Beilei
Li, Yuanguo
Yue, Donghui
Gao, Yuwei
author_sort Luo, Rongbo
collection PubMed
description BACKGROUND: Influenza viruses, especially Influenza A virus and Influenza B virus, are respiratory pathogens and can cause seasonal epidemics and pandemics. Severe influenza viruses infection induces strong host-defense response and excessive inflammatory response, resulting in acute lung damage, multiple organ failure and high mortality. Isoquercitrin is a Chinese medicine monomer, which was reported to have multiple biological activities, including antiviral activity against HSV, IAV, SARS-CoV-2 and so on. Aims of this study were to assess the in vitro anti-IAV and anti-IBV activity, evaluate the in vivo protective efficacy against lethal infection of the influenza virus and searched for the more optimal method of drug administration of isoquercitrin. METHODS: In vitro infection model (MDCK and A549 cells) and mouse lethal infection model of Influenza A virus and Influenza B virus were used to evaluate the antiviral activity of isoquercitrin. RESULTS: Isoquercitrin could significantly suppress the replication in vitro and in vivo and reduced the mortality of mouse lethal infection models. Compared with virus infection group, isoquercitrin mitigated lung and multiple organ damage. Moreover, isoquercitrin blocked hyperproduction of cytokines induced by virus infection via inactivating NF-κB signaling. Among these routes of isoquercitrin administration, intramuscular injection is a better drug delivery method. CONCLUSION: Isoquercitrin is a potential Chinese medicine monomer Against Influenza A Virus and Influenza B Virus infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00843-4.
format Online
Article
Text
id pubmed-10621105
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106211052023-11-03 A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin Luo, Rongbo Lv, Chaoxiang Wang, Tiecheng Deng, Xiuwen Sima, Mingwei Guo, Jin Qi, Jing Sun, Weiyang Shen, Beilei Li, Yuanguo Yue, Donghui Gao, Yuwei Chin Med Research BACKGROUND: Influenza viruses, especially Influenza A virus and Influenza B virus, are respiratory pathogens and can cause seasonal epidemics and pandemics. Severe influenza viruses infection induces strong host-defense response and excessive inflammatory response, resulting in acute lung damage, multiple organ failure and high mortality. Isoquercitrin is a Chinese medicine monomer, which was reported to have multiple biological activities, including antiviral activity against HSV, IAV, SARS-CoV-2 and so on. Aims of this study were to assess the in vitro anti-IAV and anti-IBV activity, evaluate the in vivo protective efficacy against lethal infection of the influenza virus and searched for the more optimal method of drug administration of isoquercitrin. METHODS: In vitro infection model (MDCK and A549 cells) and mouse lethal infection model of Influenza A virus and Influenza B virus were used to evaluate the antiviral activity of isoquercitrin. RESULTS: Isoquercitrin could significantly suppress the replication in vitro and in vivo and reduced the mortality of mouse lethal infection models. Compared with virus infection group, isoquercitrin mitigated lung and multiple organ damage. Moreover, isoquercitrin blocked hyperproduction of cytokines induced by virus infection via inactivating NF-κB signaling. Among these routes of isoquercitrin administration, intramuscular injection is a better drug delivery method. CONCLUSION: Isoquercitrin is a potential Chinese medicine monomer Against Influenza A Virus and Influenza B Virus infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00843-4. BioMed Central 2023-11-02 /pmc/articles/PMC10621105/ /pubmed/37919750 http://dx.doi.org/10.1186/s13020-023-00843-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Luo, Rongbo
Lv, Chaoxiang
Wang, Tiecheng
Deng, Xiuwen
Sima, Mingwei
Guo, Jin
Qi, Jing
Sun, Weiyang
Shen, Beilei
Li, Yuanguo
Yue, Donghui
Gao, Yuwei
A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin
title A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin
title_full A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin
title_fullStr A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin
title_full_unstemmed A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin
title_short A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin
title_sort potential chinese medicine monomer against influenza a virus and influenza b virus: isoquercitrin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621105/
https://www.ncbi.nlm.nih.gov/pubmed/37919750
http://dx.doi.org/10.1186/s13020-023-00843-4
work_keys_str_mv AT luorongbo apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT lvchaoxiang apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT wangtiecheng apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT dengxiuwen apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT simamingwei apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT guojin apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT qijing apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT sunweiyang apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT shenbeilei apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT liyuanguo apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT yuedonghui apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT gaoyuwei apotentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT luorongbo potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT lvchaoxiang potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT wangtiecheng potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT dengxiuwen potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT simamingwei potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT guojin potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT qijing potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT sunweiyang potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT shenbeilei potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT liyuanguo potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT yuedonghui potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin
AT gaoyuwei potentialchinesemedicinemonomeragainstinfluenzaavirusandinfluenzabvirusisoquercitrin